{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000143","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.482595+00:00","generated_at":"2026-05-29T09:43:44.491509+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cartesian announces positive updated Phase 2b data for Descartes-08 in MG; Phase 3 AURORA on track for H1 2025","bullets":["Descartes-08 showed 5.5-point average MG-ADL reduction at Month 4 (n=12); 33% reached minimum symptom expression at Month 6.","Responses durable through Month 12: 80% (4/5) maintained clinically meaningful improvement.","No CRS or ICANS reported; safety supports outpatient administration without lymphodepleting chemo.","Phase 3 AURORA trial (n≈100) to begin H1 2025; primary endpoint: ≥3-point MG-ADL improvement vs placebo at Month 4.","Retreated Phase 2a patients showed rapid responses again; no new safety signals."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000143","json":"https://secwatch.observer/filing/0001453687-24-000143.json","markdown":"https://secwatch.observer/filing/0001453687-24-000143.md","text":"https://secwatch.observer/filing/0001453687-24-000143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000143/0001453687-24-000143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000143/rnac-20241203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:43:44.491509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}